Loading
Life sciences · Journal article
Metabolites · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The global prevalence of obesity has reached an alarming level, placing a significant burden on public health systems and individual well-being. Bariatric surgeries (BSs) result in greater and more sustained weight reduction than emerging medications such as glucagon-like peptide-1 (GLP-1). Despite the proven effectiveness of BS, considerable inter-individual variability in postoperative outcomes persists, with differences in weight loss and remission of obesity-related comorbidities among patients. Gut microbiota gene richness has been shown to change following BS. Importantly, the influence of the gut microbiota extends beyond conventional metabolic pathways to include interactions with the host epigenome. Although growing evidence suggests that microbiota-derived metabolites can influence epigenetic processes, whether inter-individual differences in gut microbiota composition contribute to variability in postoperative weight loss and metabolic outcomes following BS remains largely unknown. The gut microbiota–epigenome axis represents a potential molecular interface between postoperative gastrointestinal remodeling and metabolic adaptation. Surgical remodeling of the gastrointestinal tract reshapes the gut microbiota and its metabolites, including short-chain fatty acids and B vitamins, which may regulate host gene expression through histone deacetylase inhibition, DNA methylation, and modulation of systemic inflammation. Current evidence suggests that postoperative probiotic supplementation may improve glucose homeostasis, lipid profiles, and vitamin B12 and D status while having little or no additional effect on postoperative weight loss. Future research should address the limitations of existing studies by conducting adequately powered, high-quality randomized controlled trials integrating multi-omics technologies and precision medicine approaches to identify microbiome-based therapeutic targets, including postbiotic interventions. Further elucidation of this axis may support the development of precision bariatric strategies, although the clinical utility of microbiome- and epigenome-targeted interventions remains to be established.